Technology area: Biotechnology & Pharmaceuticals
43 pending office actions • 24 art units • 41 examiners • 0 of 43 (0%) have an AI response strategy ready • 37 patents granted in the last 365 days
Astrazeneca AB has 39 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 37 examiners and 25 art units, demonstrating broad distribution across the biotechnology and pharmaceutical examination landscape.
FETTEROLF, BRANDON J is the busiest examiner, with 2 pending matters. No single examiner accounts for the portfolio’s full activity, so counsel should combine examiner-specific strategy with structured coordination across art units. Consistent claim terminology, disclosure support, and tracking of recurring issues can help manage the varied prosecution channels without treating the matters as a single examination record.
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (9%) |
| §103 only | 10 (23%) |
| §102 only | 1 (2%) |
| §112 only | 5 (12%) |
| Double-patenting only | 2 (5%) |
| Double-patenting + other | 9 (21%) |
| Multi-statute (no §101) | 11 (26%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FETTEROLF, BRANDON J | 2 | 51.6% | +18.5% |
| GRIZER, CASSANDRA SENN | 2 | 70.0% | +48.0% |
| HOPKINS, SAMANTHA LAKE | 1 | 60.7% | +61.5% |
| GAMBLE JR, RANDALL LEE | 1 | 51.3% | +26.9% |
| KRUSE, DAVID H | 1 | 81.4% | +9.6% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| KOSAR, ANDREW D | 1 | 41.9% | +31.9% |
| CHICKS, ASHLI ARIANA | 1 | 60.0% | +51.0% |
| YOUNG, MICAH PAUL | 1 | 55.2% | +30.0% |
| REICHERT, RACHELLE LEIGH | 1 | 30.1% | +33.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18872994 | METHODS FOR UNIFIED CONCENTRATION AND BUFFER EXCHANGE | KRUSE, DAVID H | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17917333 | COMPOSITIONS AND METHODS FOR IMPROVED SITE-SPECIFIC MODIFICATION | ALLEN, SARAH ELIZABETH | 22d overdue |
| 18252818 | PHARMACEUTICAL FORMULATION | PUTTLITZ, KARL J | 8d overdue |
| 18256484 | METHODS OF PRODUCING ADENOVIRUS | GRIZER, CASSANDRA SENN | 9d |
| 18855182 | PREDICTING ALBUMINURIA USING MACHINE LEARNING | HEIN, DEVIN C | 12d |
| 18564778 | METHODS OF TREATING BREAST CANCER | FETTEROLF, BRANDON J | 16d |
| 17754844 | MODULATORS OF PNPLA3 EXPRESSION | CHONG, KIMBERLY | 69d |
| 18855064 | PREDICTING DISEASE PROGRESSION IN PORTAL HYPERTENSION USING MACHINE LEARNING | REICHERT, RACHELLE LEIGH | 70d |
| 19099577 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | GAMBLE JR, RANDALL LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256484 | METHODS OF PRODUCING ADENOVIRUS | GRIZER, CASSANDRA SENN | 9d |
| 18564778 | METHODS OF TREATING BREAST CANCER | FETTEROLF, BRANDON J | 16d |
| 18855064 | PREDICTING DISEASE PROGRESSION IN PORTAL HYPERTENSION USING MACHINE LEARNING | REICHERT, RACHELLE LEIGH | 70d |
| 19239027 | ANTI-IL5R ANTIBODY FORMULATIONS | HOPKINS, SAMANTHA LAKE | — |
| 19099577 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | GAMBLE JR, RANDALL LEE | — |
| 18974778 | PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4- OXAZEPANE-2-CARBOXAMIDE | MOU, LIYUAN | — |
| 18870743 | COMBINATION THERAPY FOR TREATING CANCER | KOSAR, ANDREW D | — |
| 18870598 | SOLID FORMS OF HETEROCYCLYLAMIDES AS IRAK4 INHIBITORS | CHICKS, ASHLI ARIANA | — |
| Art Unit | Apps |
|---|---|
| 1641 | 4 |
| 1626 | 4 |
| 1625 | 3 |
| 1637 | 3 |
| 1672 | 3 |
| 1628 | 2 |
| 3686 | 2 |
| 1629 | 2 |
| 1643 | 2 |
| 1674 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19239027 | ANTI-IL5R ANTIBODY FORMULATIONS | HOPKINS, SAMANTHA LAKE | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Jun 16, 2025 |
| 19099577 | METHODS FOR DETECTING METABOLITES USING A MICROFLUIDIC-BASED CE-MS SYSTEM | GAMBLE JR, RANDALL LEE | 1795 | §102§103§112 | Non-Final OA | — | Pending | Jan 29, 2025 |
| 18872994 | METHODS FOR UNIFIED CONCENTRATION AND BUFFER EXCHANGE | KRUSE, DAVID H | 1663 | §103 | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18974778 | PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4- OXAZEPANE-2-CARBOXAMIDE | MOU, LIYUAN | 1628 | Other | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18870743 | COMBINATION THERAPY FOR TREATING CANCER | KOSAR, ANDREW D | 1625 | §103 | Non-Final OA | — | Pending | Dec 02, 2024 |
| 18870598 | SOLID FORMS OF HETEROCYCLYLAMIDES AS IRAK4 INHIBITORS | CHICKS, ASHLI ARIANA | 1626 | §103§112DP | Non-Final OA | — | Pending | Nov 29, 2024 |
| 18860366 | COMBINATION OF ALBUTEROL AND BUDESONIDE FOR THE TREATMENT OF ASTHMA | YOUNG, MICAH PAUL | 1618 | §102§103 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18855064 | PREDICTING DISEASE PROGRESSION IN PORTAL HYPERTENSION USING MACHINE LEARNING | REICHERT, RACHELLE LEIGH | 3686 | §101§112 | Non-Final OA | 70d | Pending | Oct 08, 2024 |
| 18855182 | PREDICTING ALBUMINURIA USING MACHINE LEARNING | HEIN, DEVIN C | 3686 | §101§103 | Final Rejection | 12d | Pending | Oct 08, 2024 |
| 18853504 | COMBINATION THERAPY FOR TREATING CANCER | FETTEROLF, BRANDON J | 1626 | §103DP | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18853520 | COMBINATION THERAPY FOR TREATING CANCER | SCHMITT, MICHAEL J | 1629 | §103 | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18840222 | COMPRESSIBLE SODIUM CAPRATE FORMULATIONS | JAUHARI, SACHI | — | §103§112 | Non-Final OA | — | Pending | Aug 21, 2024 |
| 18837956 | METHODS OF TREATING PROSTATE CANCER | ROZOF, TIMOTHY R | 1625 | §103 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18775391 | CHEMICAL COMPOUNDS | CHENG, KAREN | 1623 | §112 | Final Rejection | — | Pending | Jul 17, 2024 |
| 18753316 | ANTIBODY MOLECULES AND CONJUGATES | PETRASH, HILARY ANN | 1644 | §112Other | Non-Final OA | 54d | Pending | Jun 25, 2024 |
| 18718844 | CERTAIN 3-AZABICYCLO[3.1.0]HEXANES AS GLP-1 RECEPTOR MODULATORS | CLARK, AMY LYNN | 1628 | §112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18666615 | SPIN CHAMBER FOR AN INHALER | RUSSELL, SYDNEY REYES | 3785 | §103DP | Non-Final OA | — | Pending | May 16, 2024 |
| 18698343 | TREATMENT OF LUPUS | HAM, JIEUN | 1643 | §102§103DP | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18621483 | METHODS OF TREATING HOMOLOGOUS RECOMBINATION DEFICIENT CANCER | LI, RUIXIANG | 1674 | §102Other | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18696034 | Use of Inhibitors to Increase Efficiency of Crispr/CAS Insertions | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §102§103§112DP | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18589200 | DOSE | WEN, SHARON X | 1641 | §103DP | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18435476 | TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOUS | HADDAD, MAHER M | 1641 | §102§103§112DP | Final Rejection | — | Pending | Feb 07, 2024 |
| 18417379 | VACCINE | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18413349 | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | WEBB, WALTER E | 1612 | §103 | Final Rejection | — | Pending | Jan 16, 2024 |
| 18410094 | METHODS OF TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION | OLSON, ANDREA STEFFEL | 1693 | §103 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18542918 | TREATMENT OF AUTOIMMUNE DISEASE | DAHLE, CHUN WU | 1641 | §102§103§112 | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18539471 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | HEASLEY, MEGHAN CHRISTINE | 1626 | §112 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18564778 | METHODS OF TREATING BREAST CANCER | FETTEROLF, BRANDON J | 1626 | §102§103§112 | Non-Final OA | 16d | Pending | Nov 28, 2023 |
| 18559598 | CA S9 EFFECTOR PROTEINS WITH ENHANCED STABILITY | VYAS, KEYUR ANILKUMAR | 1637 | §101§102§103§112DP | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18550548 | CONTROL OF MULTI-GENE EXPRESSION USING SYNTHETIC PROMOTERS | MATALKAH, FATIMAH KHALAF | 1638 | §102§103§112 | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18549852 | METHODS FOR TREATING SMALL CELL LUNG CANCER AND OTHER NEUROENDOCRINE CANCERS | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Non-Final OA | 62d | Pending | Sep 08, 2023 |
| 18248280 | TREATMENT OF FLARES IN LUPUS | XIE, XIAOZHEN | 1674 | DP | Final Rejection | — | Pending | Apr 07, 2023 |
| 18247014 | COMPOUNDS AND THEIR USE IN TREATING CANCER | TOWNSLEY, SARA ELIZABETH | 1629 | §112 | Final Rejection | 87d overdue | Pending | Mar 28, 2023 |
| 18171735 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | AULAKH, CHARANJIT | 1621 | DP | Non-Final OA | — | Pending | Feb 21, 2023 |
| 17917333 | COMPOSITIONS AND METHODS FOR IMPROVED SITE-SPECIFIC MODIFICATION | ALLEN, SARAH ELIZABETH | 1637 | §101§102§103§112DP | Non-Final OA | 22d overdue | Pending | Oct 06, 2022 |
| 17754844 | MODULATORS OF PNPLA3 EXPRESSION | CHONG, KIMBERLY | 1636 | §102§103§112 | Non-Final OA | 69d | Pending | Apr 13, 2022 |
| 17765585 | METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES | CHATTIN, AMY MARIE | 1643 | §103 | Final Rejection | 15d overdue | Pending | Mar 31, 2022 |
| 18577168 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | BECKHARDT, LYNDSEY MARIE | 1613 | §103§112DP | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18256484 | METHODS OF PRODUCING ADENOVIRUS | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Final Rejection | 9d | Pending | Jun 08, 2023 |
| 18256481 | METHODS OF PURIFYING ADENOVIRUS | CORNELIUS, CLAIRE ADRIENNE | 1672 | §103§112 | Non-Final OA | — | Pending | Jun 08, 2023 |
| 18252818 | PHARMACEUTICAL FORMULATION | PUTTLITZ, KARL J | 1646 | §102§103 | Final Rejection | 8d overdue | Pending | May 12, 2023 |
| 18012705 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | KIM, SEONG JONG | 1621 | §103 | Non-Final OA | — | Pending | Dec 23, 2022 |
| 18052840 | COMPOSITION FOR TREATMENT AND PREVENTION OF COVID-19 | GODDARD, LAURA B | 1642 | §103 | Final Rejection | — | Pending | Nov 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAstrazeneca AB has 43 pending office actions as of October 2026, spread across 24 art units and 41 examiners.
Brandon J Fetterolf has the most, with 2 of Astrazeneca AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
